Moors & Cabot, Inc. Astrazeneca PLC Transaction History
Moors & Cabot, Inc.
- $2.17 Billion
- Q3 2025
A detailed history of Moors & Cabot, Inc. transactions in Astrazeneca PLC stock. As of the latest transaction made, Moors & Cabot, Inc. holds 13,711 shares of AZN stock, worth $1.23 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
13,711
Previous 8,014
71.09%
Holding current value
$1.23 Million
Previous $560,000
87.68%
% of portfolio
0.05%
Previous 0.03%
Shares
37 transactions
Others Institutions Holding AZN
# of Institutions
1,501Shares Held
501MCall Options Held
5.59MPut Options Held
3.18M-
Price T Rowe Associates Inc Baltimore, MD49.1MShares$4.39 Billion0.4% of portfolio
-
Primecap Management CO Pasadena, CA39.9MShares$3.56 Billion2.42% of portfolio
-
Bank Of America Corp Charlotte, NC32.6MShares$2.92 Billion0.18% of portfolio
-
Wellington Management Group LLP Boston, MA32.3MShares$2.89 Billion0.45% of portfolio
-
Capital International Investors Los Angeles, CA25.1MShares$2.24 Billion0.33% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $277B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...